Table 5 Multivariate analysis of factors associated with progression free survival
From: Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients
Variable | Progression-free survival (HR (95% C.I.), P – value) |
|---|---|
Stage | |
 Stage IV vs. stage I | 5.20 (0.44–61.89), P = 0.19 |
 Stage III vs. stage I | 2.18 (0.22–21.45), P = 0.50 |
 Stage II vs. stage I | 1.34 (0.08–22.94), P = 0.84 |
Debulking | |
 Suboptimal vs. optimal | 1.79 (0.57–5.62). P = 0.32 |
Pre-treatment extracellular nuclear DNA (ng/mL) | |
 High vs. Low | 3.11 (1.03–9.45). P = 0.045 |